Guidelines

Upper Urinary Tract Urothelial Cell Carcinoma

9. REFERENCES

1.Gontero, P., et al., EAU Guidelines on Non-muscle-invasive Bladder Cancer (T1, T1 and CIS), in EAU Guidelines, Edn. presented at the 39th EAU Annual Congress Paris. 2024, EAU Guidelines Office

https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

2.Witjes, J.A., et al., EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer in EAU Guidelines, Edn. presentat at the 39th EAU Annual Congress Paris. 2024, EAU Guidelines Office

https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer

3.Neuzillet, Y., et al., EAU Guidelines on Primary Urethral Carcinoma, in EAU Guidelines, Edn. presented at the 39th EAU Annual Congress Paris. 2024, EAU Guidelines Office

https://uroweb.org/guidelines/primary-urethral-carcinoma

4.Roupret, M., et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol, 2021. 79: 62.

https://www.ncbi.nlm.nih.gov/pubmed/32593530

5.Phillips, B, C.B., Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2009. http://www.cebm.net/index.aspx?o=1025)

6.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.

https://www.ncbi.nlm.nih.gov/pubmed/18467413

7.Siegel, R.L., et al. Cancer statistics, 2023. CA Cancer J Clin, 2023. 73: 17.

https://www.ncbi.nlm.nih.gov/pubmed/36633525

8.Soria, F., et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol, 2017. 35: 379.

https://www.ncbi.nlm.nih.gov/pubmed/27604375

9.Almas, B., et al. Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World J Urol, 2021. 39: 3385.

https://www.ncbi.nlm.nih.gov/pubmed/33420812

10.Shariat, S.F., et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol, 2011. 29: 481.

https://www.ncbi.nlm.nih.gov/pubmed/20886219

11.Baard, J., et al. Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. Curr Opin Urol, 2021. 31: 354.

https://www.ncbi.nlm.nih.gov/pubmed/34009177

12.Rai, B.P., et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol, 2022. 82: 182.

https://www.ncbi.nlm.nih.gov/pubmed/35393159

13.Margulis, V., et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009. 115: 1224.

https://www.ncbi.nlm.nih.gov/pubmed/19156917

14.Catto, J.W.F., et al. Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU Int, 2023. 131: 734.

https://www.ncbi.nlm.nih.gov/pubmed/36680312

15.Herout, R., et al. Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019. World J Urol, 2023. 41: 127.

https://www.ncbi.nlm.nih.gov/pubmed/36445373

16.Aziz, A., et al. Stage Migration for Upper Tract Urothelial Cell Carcinoma. Clin Genitourin Cancer, 2021. 19: e184.

https://www.ncbi.nlm.nih.gov/pubmed/33153919

17.Browne, B.M., et al. An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database. Clin Genitourin Cancer, 2018. 16: e743.

https://www.ncbi.nlm.nih.gov/pubmed/29506950

18.van Doeveren, T., et al. Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. BJU Int, 2021. 128: 343.

https://www.ncbi.nlm.nih.gov/pubmed/33690922

19.Green, D.A., et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol, 2013. 189: 1214.

https://www.ncbi.nlm.nih.gov/pubmed/23023150

20.Cosentino, M., et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol, 2013. 31: 141.

https://www.ncbi.nlm.nih.gov/pubmed/22552732

21.Singla, N., et al. A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. J Urol, 2017. 197: 1208.

https://www.ncbi.nlm.nih.gov/pubmed/27887951

22.Seisen, T., et al. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. Eur Urol, 2015. 67: 1122.

https://www.ncbi.nlm.nih.gov/pubmed/25488681

23.Li, W.M., et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol, 2010. 57: 963.

https://www.ncbi.nlm.nih.gov/pubmed/20079965

24.Audenet, F., et al. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clin Cancer Res, 2019. 25: 967.

https://www.ncbi.nlm.nih.gov/pubmed/30352907

25.Miller, E.B., et al. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. Urology, 1993. 42: 26.

https://www.ncbi.nlm.nih.gov/pubmed/8328123

26.Herr, H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol, 1998. 16: 1099.

https://www.ncbi.nlm.nih.gov/pubmed/9508196

27.Nishiyama, N., et al. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guerin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study. Urol Oncol, 2018. 36: 306 e9.

https://www.ncbi.nlm.nih.gov/pubmed/29550096

28.Sanderson, K.M., et al. Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments. BJU Int, 2007. 100: 11.

https://www.ncbi.nlm.nih.gov/pubmed/17428248

29.Ayyathurai, R., et al. Monitoring of the upper urinary tract in patients with bladder cancer. Indian J Urol, 2011. 27: 238.

https://www.ncbi.nlm.nih.gov/pubmed/21814316

30.Colin, P., et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int, 2009. 104: 1436.

https://www.ncbi.nlm.nih.gov/pubmed/19689473

31.Dickman K.G., e.a., Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers. , in Upper Tract Urothelial Carcinoma. , X.E.e. In: Shariat S., Editor. 2015, Springer: New York, NY, USA.

https://link.springer.com/chapter/10.1007/978-1-4939-1501-9_1

32.McLaughlin, J.K., et al. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res, 1992. 52: 254.

https://www.ncbi.nlm.nih.gov/pubmed/1728398

33.Crivelli, J.J., et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol, 2014. 65: 742.

https://www.ncbi.nlm.nih.gov/pubmed/23810104

34.Martin, C., et al. Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 2018. 110: 527.

https://www.ncbi.nlm.nih.gov/pubmed/29228305

35.Grollman, A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen, 2013. 54: 1.

https://www.ncbi.nlm.nih.gov/pubmed/23238808

36.National Toxicology, P. Aristolochic acids. Rep Carcinog, 2011. 12: 45.

https://www.ncbi.nlm.nih.gov/pubmed/21822318

37.Cosyns, J.P. Aristolochic acid and ‘Chinese herbs nephropathy’: a review of the evidence to date. Drug Saf, 2003. 26: 33.

https://www.ncbi.nlm.nih.gov/pubmed/12495362

38.Rosenquist, T.A., et al. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA Repair (Amst), 2016. 44: 205.

https://www.ncbi.nlm.nih.gov/pubmed/27237586

39.Jelakovic, B., et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int, 2012. 81: 559.

https://www.ncbi.nlm.nih.gov/pubmed/22071594

40.Chen, C.H., et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A, 2012. 109: 8241.

https://www.ncbi.nlm.nih.gov/pubmed/22493262

41.Nortier, J.L., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med, 2000. 342: 1686.

https://www.ncbi.nlm.nih.gov/pubmed/10841870

42.Sidorenko, V.S., et al. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis, 2014. 35: 1814.

https://www.ncbi.nlm.nih.gov/pubmed/24743514

43.Siegel, R.L., et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71: 7.

https://www.ncbi.nlm.nih.gov/pubmed/33433946

44.Hoang, M.L., et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med, 2013. 5: 197ra102.

https://www.ncbi.nlm.nih.gov/pubmed/23926200

45.Huang, C.C., et al. Gender Is a Significant Prognostic Factor for Upper Tract Urothelial Carcinoma: A Large Hospital-Based Cancer Registry Study in an Endemic Area. Front Oncol, 2019. 9: 157.

https://www.ncbi.nlm.nih.gov/pubmed/30949449

46.Xiong, G., et al. Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. Cancer Manag Res, 2018. 10: 6627.

https://www.ncbi.nlm.nih.gov/pubmed/30584358

47.Chen, C.H., et al. Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium. Cancer Epidemiol Biomarkers Prev, 2021. 30: 317.

https://www.ncbi.nlm.nih.gov/pubmed/33277322

48.Chen C-H., e.a.i.H., Arsenics and urothelial carcinoma., in Hazards of Environmental Arsenic Poisoning from Epidemic to Pandemic, C.H.Y. Chen C.J., Editor. 2011, World Scientific:: Taipei.

https://www.worldscientific.com/worldscibooks/10.1142/7569

49.Lopez, J.F., et al. Arsenic exposure is associated with significant upper tract urothelial carcinoma health care needs and elevated mortality rates. Urol Oncol, 2020. 38: 638 e7.

https://www.ncbi.nlm.nih.gov/pubmed/32088105

50.Zaitsu, M., et al. Alcohol consumption and risk of upper-tract urothelial cancer. Cancer Epidemiol, 2017. 48: 36.

https://www.ncbi.nlm.nih.gov/pubmed/28364670

51.Koornstra, J.J., et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol, 2009. 10: 400.

https://www.ncbi.nlm.nih.gov/pubmed/19341971

52.Ju, J.Y., et al. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. Am J Surg Pathol, 2018. 42: 1549.

https://www.ncbi.nlm.nih.gov/pubmed/30148743

53.Therkildsen, C., et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol, 2018. 12: 1286.

https://www.ncbi.nlm.nih.gov/pubmed/29791078

54.Kastrinos, F., et al. Development and Validation of the PREMM(5) Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol, 2017. 35: 2165.

https://www.ncbi.nlm.nih.gov/pubmed/28489507

55.Vasen, H.F., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 1999. 116: 1453.

https://www.ncbi.nlm.nih.gov/pubmed/10348829

56.Metcalfe, M.J., et al. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol, 2018. 199: 60.

https://www.ncbi.nlm.nih.gov/pubmed/28797715

57.Roupret, M., et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. J Med Genet, 2004. 41: e91.

https://www.ncbi.nlm.nih.gov/pubmed/15235034

58.Audenet, F., et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. BJU Int, 2012. 110: E583.

https://www.ncbi.nlm.nih.gov/pubmed/22703159

59.Roupret, M., et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol, 2008. 54: 1226.

https://www.ncbi.nlm.nih.gov/pubmed/18715695

60.Acher, P., et al. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int, 2010. 106: 300.

https://www.ncbi.nlm.nih.gov/pubmed/20553255

61.Gayhart, M.G., et al. Universal Mismatch Repair Protein Screening in Upper Tract Urothelial Carcinoma. Am J Clin Pathol, 2020. 154: 792.

https://www.ncbi.nlm.nih.gov/pubmed/32789450

62.Schneider, B., et al. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications. Clin Genitourin Cancer, 2020. 18: e563.

https://www.ncbi.nlm.nih.gov/pubmed/32340874

63.Ito, T., et al. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population. Jpn J Clin Oncol, 2020. 50: 80.

https://www.ncbi.nlm.nih.gov/pubmed/31665498

64.Rasmussen, M., et al. Immunohistochemical Screening of Upper Tract Urothelial Carcinomas for Lynch Syndrome Diagnostics: A Systematic Review. Urology, 2022. 165: 44.

https://www.ncbi.nlm.nih.gov/pubmed/35217028

65.Wu, J., et al. Inherited mutations in Chinese patients with upper tract urothelial carcinoma. Cell Rep Med, 2023. 4: 100883.

https://www.ncbi.nlm.nih.gov/pubmed/36630951

66.Roupret, M., et al. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol, 2012. 187: 424.

https://www.ncbi.nlm.nih.gov/pubmed/22177160

67.Kiss, B., et al. Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence. J Urol, 2017. 198: 1263.

https://www.ncbi.nlm.nih.gov/pubmed/28603003

68.Sountoulides, P., et al. Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis. J Urol, 2021. 205: 956.

https://www.ncbi.nlm.nih.gov/pubmed/33284711

69.Sakano, S., et al. Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma. Int J Clin Oncol, 2015. 20: 362.

https://www.ncbi.nlm.nih.gov/pubmed/24964974

70.Ouzzane, A., et al. Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature. Cancer Treat Rev, 2011. 37: 366.

https://www.ncbi.nlm.nih.gov/pubmed/21257269

71.Rink, M., et al. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol, 2012. 188: 398.

https://www.ncbi.nlm.nih.gov/pubmed/22698626

72.Mori, K., et al. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. J Urol, 2020. 203: 1075.

https://www.ncbi.nlm.nih.gov/pubmed/31479406

73.Perez-Montiel, D., et al. High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol, 2006. 19: 494.

https://www.ncbi.nlm.nih.gov/pubmed/16474378

74.Desai, F.S., et al. Retrospective Evaluation of Risk Factors and Immunohistochemical Findings for Pre-Neoplastic and Neoplastic lesions of Upper Urinary Tract in Patients with Chronic Nephrolithiasis. Asian Pac J Cancer Prev, 2015. 16: 8293.

https://www.ncbi.nlm.nih.gov/pubmed/26745075

75.Zamboni, S., et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU Int, 2019. 124: 738.

https://www.ncbi.nlm.nih.gov/pubmed/30908835

76.Kim, J.K., et al. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol, 2017. 35: 458 e9.

https://www.ncbi.nlm.nih.gov/pubmed/28347659

77.Bang, H., et al. Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations. Ann Diagn Pathol, 2020. 44: 151433.

https://www.ncbi.nlm.nih.gov/pubmed/31785538

78.Malouf, G.G., et al. Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas. Sci Rep, 2016. 6: 30988.

https://www.ncbi.nlm.nih.gov/pubmed/27484008

79.Hassler, M.R., et al. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. Eur Urol, 2020. 78: 209.

https://www.ncbi.nlm.nih.gov/pubmed/32571725

80.Sfakianos, J.P., et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol, 2015. 68: 970.

https://www.ncbi.nlm.nih.gov/pubmed/26278805

81.Robinson, B.D., et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun, 2019. 10: 2977.

https://www.ncbi.nlm.nih.gov/pubmed/31278255

82.Fujii, Y., et al. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021. 39: 793.

https://www.ncbi.nlm.nih.gov/pubmed/34129823

83.Soukup, V., et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol, 2017. 72: 801.

https://www.ncbi.nlm.nih.gov/pubmed/28457661

84.Subiela, J.D., et al. Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysis. Eur J Surg Oncol, 2020. 46: 1989.

https://www.ncbi.nlm.nih.gov/pubmed/32674841

85.Brierley, J.D., et al., TNM Classification of Malignant Tumours. 8th ed. 2016.

https://books.google.nl/books?id=_JaDDQAAQBAJ

86.Sauter, G., Tumours of the urinary system: non-invasive urothelial neoplasias, in WHO classification of classification of tumours of the urinary system and male genital organs, A. Sauter, Amin, M., Editor. 2004, IARC Press: Lyon.

http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016

87.Moch H, H.P., Ulbright TM, , WHO Classification of Tumours of the Urinary System and Male Genital Organs. Fourth edition. 2016, Lyon.

https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016

88.Board, W.C.o.T.E., WHO Classification of Tumours. Urinary and male genital tumours. 8th ed, ed. I.A.f.R.o. Cancer. Vol. 5th Edn.; vol 8. 2022, Lyon (France).

https://publications.iarc.fr/610

89.Raman, J.D., et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol, 2011. 29: 716.

https://www.ncbi.nlm.nih.gov/pubmed/20056458

90.Cowan, N.C., et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int, 2007. 99: 1363.

https://www.ncbi.nlm.nih.gov/pubmed/17428251

91.Janisch, F., et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol, 2020. 38: 1165.

https://www.ncbi.nlm.nih.gov/pubmed/31321509

92.Verhoest, G., et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol, 2011. 29: 495.

https://www.ncbi.nlm.nih.gov/pubmed/21681525

93.Millan-Rodriguez, F., et al. Conventional CT signs in staging transitional cell tumors of the upper urinary tract. Eur Urol, 1999. 35: 318.

https://www.ncbi.nlm.nih.gov/pubmed/10087395

94.Takahashi, N., et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol, 2010. 183: 1330.

https://www.ncbi.nlm.nih.gov/pubmed/20171676

95.Razavi, S.A., et al. Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised topic. Acad Radiol, 2012. 19: 1134.

https://www.ncbi.nlm.nih.gov/pubmed/22717592

96.Voskuilen, C.S., et al. Diagnostic Value of (18)F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2020. 3: 73.

https://www.ncbi.nlm.nih.gov/pubmed/31591037

97.The Paris System for Reporting Urinary Cytology, ed. E.M. Wojcik, Kurtycz, DFI, Rosenthal, D.L., Eds. Vol. 2nd Edn. . 2022.

https://link.springer.com/book/10.1007/978-3-030-88686-8

98.Messer, J., et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int, 2011. 108: 701.

https://www.ncbi.nlm.nih.gov/pubmed/21320275

99.Malm, C., et al. Diagnostic accuracy of upper tract urothelial carcinoma: how samples are collected matters. Scand J Urol, 2017. 51: 137.

https://www.ncbi.nlm.nih.gov/pubmed/28385123

100.Wang, L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524.

https://www.ncbi.nlm.nih.gov/pubmed/19100576

101.Lee, K.S., et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol, 2010. 65: 185.

https://www.ncbi.nlm.nih.gov/pubmed/20152273

102.Aalami, A.H., et al. Diagnostic performance of fluorescence in situ hybridization (FISH) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. Int J Clin Oncol, 2022. 27: 1605.

https://www.ncbi.nlm.nih.gov/pubmed/35856125

103.Jin, H., et al. A comprehensive comparison of fluorescence in situ hybridization and cytology for the detection of upper urinary tract urothelial carcinoma: A systematic review and meta-analysis. Medicine (Baltimore), 2018. 97: e13859.

https://www.ncbi.nlm.nih.gov/pubmed/30593189

104.Bialek, L., et al. Non-Invasive Biomarkers in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma-A Systematic Review. Cancers (Basel), 2022. 14.

https://www.ncbi.nlm.nih.gov/pubmed/35326672

105.Pycha, S., et al. Diagnostic value of Xpert(R) BC Detection, Bladder Epicheck(R), Urovysion(R) FISH and cytology in the detection of upper urinary tract urothelial carcinoma. World J Urol, 2023. 41: 1323.

https://www.ncbi.nlm.nih.gov/pubmed/36929411

106.Rojas, C.P., et al. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urologic oncology, 2013. 31: 1696.

http://linkinghub.elsevier.com/retrieve/pii/S1078143912002001?showall=true

107.Mori, K., et al. Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer, 2022. 20: 95 e1.

https://www.ncbi.nlm.nih.gov/pubmed/34764007

108.Smith, A.K., et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology, 2011. 78: 82.

https://www.ncbi.nlm.nih.gov/pubmed/21550642

109.Gallioli, A., et al. The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma. World J Urol, 2023. 41: 2743.

https://www.ncbi.nlm.nih.gov/pubmed/37668716

110.Ishikawa, S., et al. Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract. J Urol, 2010. 184: 883.

https://www.ncbi.nlm.nih.gov/pubmed/20643446

111.Clements, T., et al. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol, 2012. 26: 398.

https://www.ncbi.nlm.nih.gov/pubmed/22192113

112.Brien, J.C., et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol, 2010. 184: 69.

https://www.ncbi.nlm.nih.gov/pubmed/20478585

113.Sharma, V., et al. The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. J Urol, 2021. 206: 558.

https://www.ncbi.nlm.nih.gov/pubmed/33908802

114.Nowak, L., et al. The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. J Clin Med, 2021. 10.

https://www.ncbi.nlm.nih.gov/pubmed/34575307

115.Bus, M.T., et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol, 2015. 29: 113.

https://www.ncbi.nlm.nih.gov/pubmed/25178057

116.Knoedler, J.J., et al. Advances in the management of upper tract urothelial carcinoma: improved endoscopic management through better diagnostics. Ther Adv Urol, 2018. 10: 421.

https://www.ncbi.nlm.nih.gov/pubmed/30574202

117.Breda, A., et al. Correlation Between Confocal Laser Endomicroscopy (Cellvizio((R))) and Histological Grading of Upper Tract Urothelial Carcinoma: A Step Forward for a Better Selection of Patients Suitable for Conservative Management. Eur Urol Focus, 2018. 4: 954.

https://www.ncbi.nlm.nih.gov/pubmed/28753800

118.Bus, M.T., et al. Optical Coherence Tomography as a Tool for In Vivo Staging and Grading of Upper Urinary Tract Urothelial Carcinoma: A Study of Diagnostic Accuracy. J Urol, 2016. 196: 1749.

https://www.ncbi.nlm.nih.gov/pubmed/27475968

119.Kim, H.S., et al. Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis. Oncotarget, 2017. 8: 7464.

https://www.ncbi.nlm.nih.gov/pubmed/27448978

120.Colla Ruvolo, C., et al. Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2021. 4: 792.

https://www.ncbi.nlm.nih.gov/pubmed/33293235

121.Mori, K., et al. Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. J Urol, 2020. 204: 58.

https://www.ncbi.nlm.nih.gov/pubmed/31995432

122.Matsumoto, K., et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int, 2011. 108: E304.

https://www.ncbi.nlm.nih.gov/pubmed/21507184

123.Lonati, C., et al. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. Eur Urol Oncol, 2022. 5: 30.

https://www.ncbi.nlm.nih.gov/pubmed/34896051

124.Simsir, A., et al. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status. Int Urol Nephrol, 2011. 43: 1039.

https://www.ncbi.nlm.nih.gov/pubmed/21547471

125.Rink, M., et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol, 2013. 63: 1082.

https://www.ncbi.nlm.nih.gov/pubmed/22743166

126.Xylinas, E., et al. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int, 2014. 114: 56.

https://www.ncbi.nlm.nih.gov/pubmed/24053463

127.Shigeta, K., et al. A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2020. 3: 756.

https://www.ncbi.nlm.nih.gov/pubmed/31395480

128.Sundi, D., et al. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol, 2012. 30: 266.

https://www.ncbi.nlm.nih.gov/pubmed/20869888

129.Gadzinski, A.J., et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol, 2012. 26: 566.

https://www.ncbi.nlm.nih.gov/pubmed/21879886

130.Lee, J.N., et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol, 2014. 110: 468.

https://www.ncbi.nlm.nih.gov/pubmed/25059848

131.Waldert, M., et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int, 2010. 105: 812.

https://www.ncbi.nlm.nih.gov/pubmed/19732052

132.Xia, L., et al. Impact of surgical waiting time on survival in patients with upper tract urothelial carcinoma: A national cancer database study. Urol Oncol, 2018. 36: 10 e15.

https://www.ncbi.nlm.nih.gov/pubmed/29031419

133.Kluth, L.A., et al. Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU Int, 2014. 113: 911.

https://www.ncbi.nlm.nih.gov/pubmed/24053651

134.Aziz, A., et al. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. Urol Oncol, 2014. 32: 1141.

https://www.ncbi.nlm.nih.gov/pubmed/24856977

135.Chromecki, T.F., et al. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World J Urol, 2011. 29: 473.

https://www.ncbi.nlm.nih.gov/pubmed/21499902

136.Tanaka, N., et al. Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions. BJU Int, 2013. 112: E28.

https://www.ncbi.nlm.nih.gov/pubmed/23795795

137.Berod, A.A., et al. The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. BJU Int, 2012. 110: E1035.

https://www.ncbi.nlm.nih.gov/pubmed/22568669

138.Carrion, A., et al. Intraoperative prognostic factors and atypical patterns of recurrence in patients with upper urinary tract urothelial carcinoma treated with laparoscopic radical nephroureterectomy. Scand J Urol, 2016. 50: 305.

https://www.ncbi.nlm.nih.gov/pubmed/26926709

139.Ehdaie, B., et al. Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. J Urol, 2011. 186: 66.

https://www.ncbi.nlm.nih.gov/pubmed/21571333

140.Yeh, H.C., et al. Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World J Urol, 2021. 39: 491.

https://www.ncbi.nlm.nih.gov/pubmed/32318857

141.Dalpiaz, O., et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Cancer, 2014. 110: 2531.

https://www.ncbi.nlm.nih.gov/pubmed/24691424

142.Vartolomei, M.D., et al. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. World J Urol, 2018. 36: 1019.

https://www.ncbi.nlm.nih.gov/pubmed/29468284

143.Mori, K., et al. Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. Urol Oncol, 2020. 38: 315.

https://www.ncbi.nlm.nih.gov/pubmed/32088103

144.Zheng, Y., et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol, 2019. 9: 914.

https://www.ncbi.nlm.nih.gov/pubmed/31620369

145.Liu, J., et al. The prognostic significance of preoperative serum albumin in urothelial carcinoma: a systematic review and meta-analysis. Biosci Rep, 2018. 38.

https://www.ncbi.nlm.nih.gov/pubmed/29685957

146.Soria, F., et al. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. Urol Oncol, 2020. 38: 602 e11.

https://www.ncbi.nlm.nih.gov/pubmed/32037197

147.Mori, K., et al. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. Urol Oncol, 2020. 38: 601 e17.

https://www.ncbi.nlm.nih.gov/pubmed/32127252

148.Xu, H., et al. Pretreatment elevated fibrinogen level predicts worse oncologic outcomes in upper tract urothelial carcinoma. Asian J Androl, 2020. 22: 177.

https://www.ncbi.nlm.nih.gov/pubmed/31169138

149.Mbeutcha, A., et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol, 2017. 35: 337.

https://www.ncbi.nlm.nih.gov/pubmed/27101100

150.Liu, J., et al. Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning. BMC Cancer, 2023. 23: 574.

https://www.ncbi.nlm.nih.gov/pubmed/37349696

151.Rosiello, G., et al. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. J Surg Oncol, 2020. 121: 1154.

https://www.ncbi.nlm.nih.gov/pubmed/32107785

152.Seisen, T., et al. Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. Eur Urol Focus, 2021. 7: 1075.

https://www.ncbi.nlm.nih.gov/pubmed/33463527

153.Ouzzane, A., et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol, 2011. 60: 1258.

https://www.ncbi.nlm.nih.gov/pubmed/21665356

154.Yafi, F.A., et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int, 2012. 110: E7.

https://www.ncbi.nlm.nih.gov/pubmed/22177329

155.Hurel, S., et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol, 2015. 33: 335.

https://www.ncbi.nlm.nih.gov/pubmed/24810657

156.Chromecki, T.F., et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol, 2012. 61: 245.

https://www.ncbi.nlm.nih.gov/pubmed/21975249

157.Fradet, V., et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urol Oncol, 2014. 32: 839.

https://www.ncbi.nlm.nih.gov/pubmed/24856978

158.Messer, J.C., et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol, 2013. 31: 904.

https://www.ncbi.nlm.nih.gov/pubmed/21906967

159.Ito, Y., et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol, 2011. 185: 1621.

https://www.ncbi.nlm.nih.gov/pubmed/21419429

160.Ye, T., et al. Prognostic Value of Preoperative Hydronephrosis in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urinary Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol, 2020. 10: 600511.

https://www.ncbi.nlm.nih.gov/pubmed/33425758

161.Ma, R., et al. Prognostic Value of Tumor Size in Patients with Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 2022. 42: 19.

https://www.ncbi.nlm.nih.gov/pubmed/35783990

162.Colla Ruvolo, C., et al. Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. Eur Urol Focus, 2022. 8: 498.

https://www.ncbi.nlm.nih.gov/pubmed/33737024

163.Foerster, B., et al. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). Clin Genitourin Cancer, 2021. 19: 272 e1.

https://www.ncbi.nlm.nih.gov/pubmed/33046411

164.Yu, J., et al. Impact of squamous differentiation on intravesical recurrence and prognosis of patients with upper tract urothelial carcinoma. Ann Transl Med, 2019. 7: 377.

https://www.ncbi.nlm.nih.gov/pubmed/31555691

165.Pelcovits, A., et al. Outcomes of upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: implications for multi-modal management. World J Urol, 2020. 38: 1243.

https://www.ncbi.nlm.nih.gov/pubmed/31388818

166.Fajkovic, H., et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol, 2012. 187: 845.

https://www.ncbi.nlm.nih.gov/pubmed/22248522

167.Roscigno, M., et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol, 2011. 60: 776.

https://www.ncbi.nlm.nih.gov/pubmed/21798659

168.Raza, S.J., et al. Lymph node density for stratification of survival outcomes with node positive upper tract urothelial carcinoma. Can J Urol, 2019. 26: 9852.

https://www.ncbi.nlm.nih.gov/pubmed/31469641

169.Roupret, M., et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol, 2013. 189: 1662.

https://www.ncbi.nlm.nih.gov/pubmed/23103802

170.Lughezzani, G., et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology, 2010. 75: 118.

https://www.ncbi.nlm.nih.gov/pubmed/19864000

171.Nazzani, S., et al. Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. Eur J Surg Oncol, 2019. 45: 1238.

https://www.ncbi.nlm.nih.gov/pubmed/30563773

172.Yanagisawa, T., et al. Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023. Curr Opin Urol, 2023. 33: 258.

https://www.ncbi.nlm.nih.gov/pubmed/37014743

173.Kikuchi, E., et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol, 2009. 27: 612.

https://www.ncbi.nlm.nih.gov/pubmed/19075275

174.Novara, G., et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol, 2010. 57: 1064.

https://www.ncbi.nlm.nih.gov/pubmed/20071073

175.Liu, W., et al. Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. Dis Markers, 2019. 2019: 7386140.

https://www.ncbi.nlm.nih.gov/pubmed/31565103

176.Samaratunga, H., et al. Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Am J Surg Pathol, 2019. 43: e1.

https://www.ncbi.nlm.nih.gov/pubmed/31192862

177.Stangl-Kremser, J., et al. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis. Urol Oncol, 2022. 40: 243.

https://www.ncbi.nlm.nih.gov/pubmed/35241364

178.Colin, P., et al. Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol, 2012. 19: 3613.

https://www.ncbi.nlm.nih.gov/pubmed/22843187

179.Sharma, G., et al. Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis. Int Braz J Urol, 2022. 48: 406.

https://www.ncbi.nlm.nih.gov/pubmed/34003609

180.Martini, A., et al. Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU Int, 2019. 124: 665.

https://www.ncbi.nlm.nih.gov/pubmed/30801918

181.Singla, N., et al. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urol Oncol, 2020. 38: 933 e7.

https://www.ncbi.nlm.nih.gov/pubmed/32430254

182.Remzi, M., et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int, 2009. 103: 307.

https://www.ncbi.nlm.nih.gov/pubmed/18990163

183.Fritsche, H.M., et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol, 2012. 30: 666.

https://www.ncbi.nlm.nih.gov/pubmed/20933445

184.Liu, H.Y., et al. The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis. Front Oncol, 2021. 11: 613696.

https://www.ncbi.nlm.nih.gov/pubmed/33718167

185.Gao, X., et al. Concomitant carcinoma in situ as a prognostic factor in the upper tract urothelial carcinoma after radical nephroureterectomy: A systematic review and meta-analysis. Urol Oncol, 2020. 38: 574.

https://www.ncbi.nlm.nih.gov/pubmed/32273049

186.Redrow, G.P., et al. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol, 2017. 197: 287.

https://www.ncbi.nlm.nih.gov/pubmed/27664578

187.Roscigno, M., et al. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. BJU Int, 2012. 110: 674.

https://www.ncbi.nlm.nih.gov/pubmed/22348322

188.Roupret, M., et al. A new proposal to risk stratify urothelial carcinomas of the upper urinary tract (UTUCs) in a predefinitive treatment setting: low-risk versus high-risk UTUCs. Eur Urol, 2014. 66: 181.

https://www.ncbi.nlm.nih.gov/pubmed/24361259

189.Seisen, T., et al. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol, 2015. 12: 155.

https://www.ncbi.nlm.nih.gov/pubmed/25708579

190.Favaretto, R.L., et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int, 2012. 109: 77.

https://www.ncbi.nlm.nih.gov/pubmed/21631698

191.Petros, F.G., et al. Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. Urol Oncol, 2019. 37: 292 e1.

https://www.ncbi.nlm.nih.gov/pubmed/30584035

192.Yoshida, T., et al. Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma. Cancer Med, 2020. 9: 3733.

https://www.ncbi.nlm.nih.gov/pubmed/32253820

193.Margulis, V., et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol, 2010. 184: 453.

https://www.ncbi.nlm.nih.gov/pubmed/20620397

194.Venkat, S., et al. Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma. Urol Oncol, 2022. 40: 108 e11.

https://www.ncbi.nlm.nih.gov/pubmed/35034804

195.Foerster, B., et al. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. Eur Urol, 2021. 80: 507.

https://www.ncbi.nlm.nih.gov/pubmed/34023164

196.Katayama, S., et al. Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. Eur Urol Focus, 2022. 8: 761.

https://www.ncbi.nlm.nih.gov/pubmed/34053904

197.Marcq, G., et al. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. Eur Urol Focus, 2022. 8: 491.

https://www.ncbi.nlm.nih.gov/pubmed/33773965

198.Cha, E.K., et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol, 2012. 61: 818.

https://www.ncbi.nlm.nih.gov/pubmed/22284969

199.Yates, D.R., et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer, 2012. 106: 1083.

https://www.ncbi.nlm.nih.gov/pubmed/22374463

200.Seisen, T., et al. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int, 2014. 114: 733.

https://www.ncbi.nlm.nih.gov/pubmed/24447471

201.Ku, J.H., et al. External validation of an online nomogram in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Br J Cancer, 2013. 109: 1130.

https://www.ncbi.nlm.nih.gov/pubmed/23949152

202.Krabbe, L.M., et al. Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol, 2017. 197: 580.

https://www.ncbi.nlm.nih.gov/pubmed/27670916

203.Zhang, G.L., et al. A Model for the Prediction of Survival in Patients With Upper Tract Urothelial Carcinoma After Surgery. Dose Response, 2019. 17: 1559325819882872.

https://www.ncbi.nlm.nih.gov/pubmed/31662711

204.Zhang, X., et al. Development and Validation of a Model for Predicting Intravesical Recurrence in Organ-confined Upper Urinary Tract Urothelial Carcinoma Patients after Radical Nephroureterectomy: a Retrospective Study in One Center with Long-term Follow-up. Pathol Oncol Res, 2020. 26: 1741.

https://www.ncbi.nlm.nih.gov/pubmed/31643022

205.Sheu, Z.L., et al. Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy. Sci Rep, 2021. 11: 19059.

https://www.ncbi.nlm.nih.gov/pubmed/34561545

206.Marchioni, M., et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int, 2017. 120: 313.

https://www.ncbi.nlm.nih.gov/pubmed/28621055

207.Guo, R.Q., et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU Int, 2018. 121: 184.

https://www.ncbi.nlm.nih.gov/pubmed/29032580

208.Seisen, T., et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol, 2016. 70: 1052.

https://www.ncbi.nlm.nih.gov/pubmed/27477528

209.Cutress, M.L., et al. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int, 2012. 110: 1608.

https://www.ncbi.nlm.nih.gov/pubmed/22564677

210.Cutress, M.L., et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int, 2012. 110: 614.

https://www.ncbi.nlm.nih.gov/pubmed/22471401

211.Cornu, J.N., et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol, 2010. 28: 151.

https://www.ncbi.nlm.nih.gov/pubmed/20044752

212.Villa, L., et al. Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol, 2016. 34: 1201.

https://www.ncbi.nlm.nih.gov/pubmed/26699629

213.Vemana, G., et al. Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data. Urology, 2016. 95: 115.

https://www.ncbi.nlm.nih.gov/pubmed/27233931

214.Kawada, T., et al. Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis. Eur Urol Focus, 2023. 9: 236.

https://www.ncbi.nlm.nih.gov/pubmed/36463089

215.Roupret, M., et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol, 2007. 51: 709.

https://www.ncbi.nlm.nih.gov/pubmed/16911852

216.Jeldres, C., et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol, 2010. 183: 1324.

https://www.ncbi.nlm.nih.gov/pubmed/20171666

217.Colin, P., et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int, 2012. 110: 1134.

https://www.ncbi.nlm.nih.gov/pubmed/22394612

218.Lughezzani, G., et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer, 2009. 45: 3291.

https://www.ncbi.nlm.nih.gov/pubmed/19615885

219.Steffens, J., et al. Partial nephrectomy and autotransplantation with pyelovesicostomy for renal urothelial carcinoma in solitary kidneys: a clinical update. BJU Int, 2007. 99: 1020.

https://www.ncbi.nlm.nih.gov/pubmed/17309555

220.Ou, Y.C., et al. Long-term outcomes of total ureterectomy with ileal-ureteral substitution treatment for ureteral cancer: a single-center experience. BMC Urol, 2018. 18: 73.

https://www.ncbi.nlm.nih.gov/pubmed/30170590

221.Matin, S.F., et al. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol, 2022. 207: 779.

https://www.ncbi.nlm.nih.gov/pubmed/34915741

222.Giannarini, G., et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol, 2011. 60: 955.

https://www.ncbi.nlm.nih.gov/pubmed/21807456

223.Irie, A., et al. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology, 2002. 59: 53.

https://www.ncbi.nlm.nih.gov/pubmed/11796281

224.Horiguchi, H., et al. Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol, 2018. 35: 41.

https://www.ncbi.nlm.nih.gov/pubmed/29480348

225.Tomisaki, I., et al. Efficacy and Tolerability of Bacillus Calmette-Guerin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ. Cancer Invest, 2018. 36: 152.

https://www.ncbi.nlm.nih.gov/pubmed/29393701

226.Yossepowitch, O., et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol, 2005. 173: 890.

https://www.ncbi.nlm.nih.gov/pubmed/15711312

227.Foerster, B., et al. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol, 2019. 37: 430.

https://www.ncbi.nlm.nih.gov/pubmed/30846387

228.Gallioli, A., et al. Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial. J Endourol, 2020. 34: 573.

https://www.ncbi.nlm.nih.gov/pubmed/32164441

229.Roupret, M., et al. Oncological risk of laparoscopic surgery in urothelial carcinomas. World J Urol, 2009. 27: 81.

https://www.ncbi.nlm.nih.gov/pubmed/19020880

230.Ong, A.M., et al. Trocar site recurrence after laparoscopic nephroureterectomy. J Urol, 2003. 170: 1301.

https://www.ncbi.nlm.nih.gov/pubmed/14501747

231.Peyronnet, B., et al. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. Eur Urol Focus, 2019. 5: 205.

https://www.ncbi.nlm.nih.gov/pubmed/29154042

232.Simone, G., et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol, 2009. 56: 520.

https://www.ncbi.nlm.nih.gov/pubmed/19560259

233.Favaretto, R.L., et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol, 2010. 58: 645.

https://www.ncbi.nlm.nih.gov/pubmed/20724065

234.Walton, T.J., et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int, 2011. 108: 406.

https://www.ncbi.nlm.nih.gov/pubmed/21078048

235.Ni, S., et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol, 2012. 61: 1142.

https://www.ncbi.nlm.nih.gov/pubmed/22349569

236.Ariane, M.M., et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol, 2012. 19: 301.

https://www.ncbi.nlm.nih.gov/pubmed/21691878

237.Adibi, M., et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol, 2012. 19: 1060.

https://www.ncbi.nlm.nih.gov/pubmed/22882743

238.Sui, W., et al. The Impact of Hospital Volume on Short-term and Long-term Outcomes for Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Urology, 2021. 147: 135.

https://www.ncbi.nlm.nih.gov/pubmed/32891638

239.Veccia, A., et al. Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair “tetrafecta” Analysis (ROBUUST Collaborative Group). J Endourol, 2022. 36: 752.

https://www.ncbi.nlm.nih.gov/pubmed/35019760

240.Ji, R., et al. Robot-assisted vs. laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis based on comparative studies. Front Oncol, 2022. 12: 964256.

https://www.ncbi.nlm.nih.gov/pubmed/35992849

241.O’Sullivan, N.J., et al. Robotic-assisted versus laparoscopic nephroureterectomy; a systematic review and meta-analysis. BJUI Compass, 2023. 4: 246.

https://www.ncbi.nlm.nih.gov/pubmed/37025468

242.Clements, M.B., et al. Robotic-Assisted Surgery for Upper Tract Urothelial Carcinoma: A Comparative Survival Analysis. Ann Surg Oncol, 2018. 25: 2550.

https://www.ncbi.nlm.nih.gov/pubmed/29948423

243.Rodriguez, J.F., et al. Utilization and Outcomes of Nephroureterectomy for Upper Tract Urothelial Carcinoma by Surgical Approach. J Endourol, 2017. 31: 661.

https://www.ncbi.nlm.nih.gov/pubmed/28537436

244.Aboumohamed, A.A., et al. Oncologic Outcomes Following Robot-Assisted Laparoscopic Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma. J Urol, 2015. 194: 1561.

https://www.ncbi.nlm.nih.gov/pubmed/26192256

245.Grossmann, N.C., et al. Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis. Cancers (Basel), 2023. 15.

https://www.ncbi.nlm.nih.gov/pubmed/36900201

246.Xylinas, E., et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol, 2014. 65: 210.

https://www.ncbi.nlm.nih.gov/pubmed/22579047

247.Xylinas, E., et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol, 2014. 65: 650.

https://www.ncbi.nlm.nih.gov/pubmed/24070577

248.Phe, V., et al. Does the surgical technique for management of the distal ureter influence the outcome after nephroureterectomy? BJU Int, 2011. 108: 130.

https://www.ncbi.nlm.nih.gov/pubmed/21070580

249.Kondo, T., et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol, 2010. 17: 848.

https://www.ncbi.nlm.nih.gov/pubmed/20812922

250.Dominguez-Escrig, J.L., et al. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus, 2019. 5: 224.

https://www.ncbi.nlm.nih.gov/pubmed/29158169

251.Dong, F., et al. Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study. Int J Clin Oncol, 2019. 24: 296.

https://www.ncbi.nlm.nih.gov/pubmed/30334174

252.Lenis, A.T., et al. Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol, 2018. 36: 9 e1.

https://www.ncbi.nlm.nih.gov/pubmed/29066013

253.Moschini, M., et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol, 2017. 35: 1541.

https://www.ncbi.nlm.nih.gov/pubmed/28247066

254.Zareba, P., et al. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer, 2017. 123: 1741.

https://www.ncbi.nlm.nih.gov/pubmed/28152158

255.Xylinas, E., et al. External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. Urol Oncol, 2017. 35: 33 e21.

https://www.ncbi.nlm.nih.gov/pubmed/27816402

256.Xylinas, E., et al. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. J Urol, 2013. 189: 468.

https://www.ncbi.nlm.nih.gov/pubmed/23253960

257.Matin, S.F., et al. Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. J Urol, 2015. 194: 1567.

https://www.ncbi.nlm.nih.gov/pubmed/26094807

258.Kondo, T., et al. Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study. Int J Urol, 2014. 21: 453.

https://www.ncbi.nlm.nih.gov/pubmed/24754341

259.Masson-Lecomte, A., et al. Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee. Cancers (Basel), 2022. 14.

https://www.ncbi.nlm.nih.gov/pubmed/36358870

260.Matin, S.F., et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer, 2010. 116: 3127.

https://www.ncbi.nlm.nih.gov/pubmed/20564621

261.Liao, R.S., et al. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol, 2018. 200: 68.

https://www.ncbi.nlm.nih.gov/pubmed/29307680

262.Meng, X., et al. High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology, 2019. 129: 146.

https://www.ncbi.nlm.nih.gov/pubmed/30930207

263.Almassi, N., et al. Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. Clin Genitourin Cancer, 2018. 16: e1237.

https://www.ncbi.nlm.nih.gov/pubmed/30217764

264.Kubota, Y., et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget, 2017. 8: 101500.

https://www.ncbi.nlm.nih.gov/pubmed/29254181

265.Hosogoe, S., et al. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. Eur Urol Focus, 2018. 4: 946.

https://www.ncbi.nlm.nih.gov/pubmed/28753881

266.Porten, S., et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer, 2014. 120: 1794.

https://www.ncbi.nlm.nih.gov/pubmed/24633966

267.Margulis, V., et al. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol, 2020. 203: 690.

https://www.ncbi.nlm.nih.gov/pubmed/31702432

268.Coleman, J.A., et al. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol, 2023. 41: 1618.

https://www.ncbi.nlm.nih.gov/pubmed/36603175

269.Leow, J.J., et al. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol, 2021. 79: 635.

https://www.ncbi.nlm.nih.gov/pubmed/32798146

270.Necchi, A., et al. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol, 2022. 40: 10 e1.

https://www.ncbi.nlm.nih.gov/pubmed/34147313

271.O’Brien, T., et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol, 2011. 60: 703.

https://www.ncbi.nlm.nih.gov/pubmed/21684068

272.Ito, A., et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol, 2013. 31: 1422.

https://www.ncbi.nlm.nih.gov/pubmed/23460707

273.Hwang, E.C., et al. Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma. Cochrane Database Syst Rev, 2019. 5: CD013160.

https://www.ncbi.nlm.nih.gov/pubmed/31102534

274.Fang, D., et al. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int, 2013. 91: 291.

https://www.ncbi.nlm.nih.gov/pubmed/23948770

275.Freifeld, Y., et al. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urol Oncol, 2020. 38: 737 e11.

https://www.ncbi.nlm.nih.gov/pubmed/32641241

276.Harraz, A.M., et al. Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial. Clin Genitourin Cancer, 2019. 17: e1108.

https://www.ncbi.nlm.nih.gov/pubmed/31594736

277.Yamamoto, S., et al. Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol, 2019. 26: 791.

https://www.ncbi.nlm.nih.gov/pubmed/31081198

278.Birtle, A., et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 2020. 395: 1268.

https://www.ncbi.nlm.nih.gov/pubmed/32145825

279.Xylinas, E., et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int, 2013. 112: 453.

https://www.ncbi.nlm.nih.gov/pubmed/23464979

280.Kaag, M., et al. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int, 2014. 114: 674.

https://www.ncbi.nlm.nih.gov/pubmed/24314050

281.Kaag, M.G., et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol, 2010. 58: 581.

https://www.ncbi.nlm.nih.gov/pubmed/20619530

282.Tully, K.H., et al. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol, 2020. 38: 2227.

https://www.ncbi.nlm.nih.gov/pubmed/31748954

283.Bajorin, D.F., et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med, 2021. 384: 2102.

https://www.ncbi.nlm.nih.gov/pubmed/34077643

284.Agency, E.M. European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%. 2022. 2022.

https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf

285.Laukhtina, E., et al. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol, 2022. 169: 103570.

https://www.ncbi.nlm.nih.gov/pubmed/34902554

286.Hahn, A.W., et al. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. Anticancer Res, 2016. 36: 4051.

https://www.ncbi.nlm.nih.gov/pubmed/27466512

287.Huang, Y.C., et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep, 2016. 6: 38175.

https://www.ncbi.nlm.nih.gov/pubmed/27910890

288.Czito, B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172: 1271.

https://www.ncbi.nlm.nih.gov/pubmed/15371822

289.Iwata, T., et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol, 2019. 37: 659.

https://www.ncbi.nlm.nih.gov/pubmed/31255542

290.Powles, T., et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2020. 383: 1218.

https://www.ncbi.nlm.nih.gov/pubmed/32945632

291.Piontkowski, A.J., et al. Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: Analysis of NCDB registry. Urol Oncol, 2022. 40: 409 e9.

https://www.ncbi.nlm.nih.gov/pubmed/35623996

292.Shigeta, K., et al. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Urol Oncol, 2022. 40: 105 e19.

https://www.ncbi.nlm.nih.gov/pubmed/34454822

293.Moschini, M., et al. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. J Urol, 2018. 199: 1149.

https://www.ncbi.nlm.nih.gov/pubmed/29158104

294.Gust, K.M., et al. Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. Transl Androl Urol, 2021. 10: 4051.

https://www.ncbi.nlm.nih.gov/pubmed/34804847

295.Powles, T., et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol, 2021. 22: 931.

https://www.ncbi.nlm.nih.gov/pubmed/34051178

296.Galsky, M.D., et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2020. 395: 1547.

https://www.ncbi.nlm.nih.gov/pubmed/32416780

297.Powles, T., et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 2020. 21: 1574.

https://www.ncbi.nlm.nih.gov/pubmed/32971005

298.van der Heijden, M.S., et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med, 2023. 389: 1778.

https://www.ncbi.nlm.nih.gov/pubmed/37870949

299.De Santis, M., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol, 2012. 30: 191.

https://www.ncbi.nlm.nih.gov/pubmed/22162575

300.Richters, A., et al. Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. Clin Genitourin Cancer, 2022. 20: e346.

https://www.ncbi.nlm.nih.gov/pubmed/35039230

301.Powles, T., et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. Journal of Clinical Oncology, 2020. 38: LBA1.

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA1

302.Galsky, M.D., et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol, 2020. 38: 1797.

https://www.ncbi.nlm.nih.gov/pubmed/32271672

303.Vuky, J., et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol, 2020. 38: 2658.

https://www.ncbi.nlm.nih.gov/pubmed/32552471

304.Balar, A.V., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, 2017. 389: 67.

https://www.ncbi.nlm.nih.gov/pubmed/27939400

305.Bellmunt, J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med, 2017. 376: 1015.

https://www.ncbi.nlm.nih.gov/pubmed/28212060

306.Powles, T., et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2018. 391: 748.

https://www.ncbi.nlm.nih.gov/pubmed/29268948

307.Sharma, P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2017. 18: 312.

https://www.ncbi.nlm.nih.gov/pubmed/28131785

308.Patel, M.R., et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol, 2018. 19: 51.

https://www.ncbi.nlm.nih.gov/pubmed/29217288

309.Apolo, A.B., et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol, 2017. 35: 2117.

https://www.ncbi.nlm.nih.gov/pubmed/28375787

310.Powles, T., et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol, 2017. 3: e172411.

https://www.ncbi.nlm.nih.gov/pubmed/28817753

311.Sharma, P., et al. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol, 2019. 37: 1608.

https://www.ncbi.nlm.nih.gov/pubmed/31100038

312.Siefker-Radtke, A., et al. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol, 2018. 15: 112.

https://www.ncbi.nlm.nih.gov/pubmed/29205200

313.Loriot, Y., et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2019. 381: 338.

https://www.ncbi.nlm.nih.gov/pubmed/31340094

314.Loriot, Y., et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2023. 389: 1961.

https://www.ncbi.nlm.nih.gov/pubmed/37870920

315.De Lorenzis, E., et al. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma. Genes (Basel), 2021. 12.

https://www.ncbi.nlm.nih.gov/pubmed/33668859

316.Yu, E.Y., et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV1397645928201): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2021. 22: 872.

https://www.ncbi.nlm.nih.gov/pubmed/33991512

317.Powles, T., et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med, 2021. 384: 1125.

https://www.ncbi.nlm.nih.gov/pubmed/33577729

318.Tagawa, S.T., et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol, 2021. 39: 2474.

https://www.ncbi.nlm.nih.gov/pubmed/33929895

319.Drakaki, A., et al. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer, 2020. 6: 43.


320.Seisen, T., et al. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol, 2017. 71: 714.

https://www.ncbi.nlm.nih.gov/pubmed/27912971

321.Moschini, M., et al. Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. Eur Urol Oncol, 2020. 3: 94.

https://www.ncbi.nlm.nih.gov/pubmed/31307962

322.Zhang, X., et al. The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma. Cancer Med, 2021. 10: 8079.

https://www.ncbi.nlm.nih.gov/pubmed/34647688

323.Dong, F., et al. How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data. Clin Exp Metastasis, 2017. 34: 467.

https://www.ncbi.nlm.nih.gov/pubmed/29500709

324.Nazzani, S., et al. Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Clin Genitourin Cancer, 2019. 17: e602.

https://www.ncbi.nlm.nih.gov/pubmed/31005472

325.Siefker-Radtke, A.O., et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol, 2004. 171: 145.

https://www.ncbi.nlm.nih.gov/pubmed/14665863

326.Abe, T., et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol, 2007. 52: 1106.

https://www.ncbi.nlm.nih.gov/pubmed/17367917

327.Lehmann, J., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol, 2009. 55: 1293.

https://www.ncbi.nlm.nih.gov/pubmed/19058907

328.Faltas, B.M., et al. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol, 2018. 36: 9 e11.

https://www.ncbi.nlm.nih.gov/pubmed/28988653

329.Lemke, E., et al. The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? Clin Genitourin Cancer, 2020. 18: e478.

https://www.ncbi.nlm.nih.gov/pubmed/32085986

330.Oge, O., et al. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol, 2000. 37: 271.

https://www.ncbi.nlm.nih.gov/pubmed/10720851

331.Holmang, S., et al. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol, 2006. 175: 69.

https://www.ncbi.nlm.nih.gov/pubmed/16406872

332.Shigeta, K., et al. The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma. J Urol, 2017. 198: 1278.

https://www.ncbi.nlm.nih.gov/pubmed/28634017

333.Martini, A., et al. Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2022. 5: 451.

https://www.ncbi.nlm.nih.gov/pubmed/35504834

334.Holmang, S., et al. Long-term follow-up of patients with tumours of the renal pelvis and ureter: how often is a bladder tumour diagnosed after five tumour-free years? Scand J Urol, 2014. 48: 65.

https://www.ncbi.nlm.nih.gov/pubmed/23883372

335.Mandalapu, R.S., et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol, 2017. 35: 355.

https://www.ncbi.nlm.nih.gov/pubmed/27233780

336.Bagley, D.H., et al. Ureteroscopic laser treatment of upper urinary tract neoplasms. World J Urol, 2010. 28: 143.

https://www.ncbi.nlm.nih.gov/pubmed/20229233

337.Mohapatra, A., et al. Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management. Int Urol Nephrol, 2020. 52: 1465.

https://www.ncbi.nlm.nih.gov/pubmed/32157621

338.Xylinas, E., et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol, 2012. 61: 1069.

https://www.ncbi.nlm.nih.gov/pubmed/22402109

339.Territo, A., et al. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial. J Urol, 2022. 208: 570.

https://www.ncbi.nlm.nih.gov/pubmed/35549312

340.Zhang, M.L., et al. A review of upper urinary tract cytology performance before and after the implementation of The Paris System. Cancer Cytopathol, 2021. 129: 264.

https://www.ncbi.nlm.nih.gov/pubmed/32897658

341.Chouhan, H., et al. Evaluation of Urinalysis-Based Screening for Urothelial Carcinoma in Patients With Lynch Syndrome. Dis Colon Rectum, 2022. 65: 40.

https://www.ncbi.nlm.nih.gov/pubmed/34882627

342.Myrhoj, T., et al. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer, 2008. 7: 303.

https://www.ncbi.nlm.nih.gov/pubmed/18389386